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Conditional Survival in Patients with Thyroid Cancer
Mousumi Banerjee,1 Daniel G. Muenz,1 Francis P. Worden,2 Sandra L. Wong,3 and Megan R. Haymart2,4
Background: Thyroid cancer is an increasingly common malignancy. Although likelihood of survival from
well-differentiated thyroid cancer can vary by disease severity, it is not known how patients’ life expectancies
change the farther they are from time of diagnosis.
Methods: Using data from the Surveillance, Epidemiology, End Results (SEER) registry, we selected patients
diagnosed with well-differentiated thyroid cancer (N = 43,392) between 1998 and 2005. Patients were followed
for up to 12 years. Conditional survival estimates by SEER stage and age were obtained based on Cox
proportional hazards regression model of disease-specific survival.
Results: Patients with localized thyroid cancer have excellent conditional 5-year survival, irrespective of where
they are in their survivorship phase. Patients with regional thyroid cancer have relatively stable conditional 5-
year survival, whereas for patients with distant thyroid cancer there is gradual improvement the farther from
time of diagnosis. Age and gender influence conditional survival. Similarly, age has a strong effect on disease-
specific survival for patients with thyroid cancer with localized (hazard ratio [HR] 88.7 [95% confidence
interval {CI} 26.3–552), comparing age ‡ 80 with < 30 years), regional (HR 105 [95% CI 52.6–250]), and
distant disease [HR 86.8 (95% CI 32.5–354)]. Male gender is also associated with a significantly worse disease-
specific survival among patients with regional disease (HR 1.56 [95% CI 1.31–1.85]) but not among patients
with localized or distant disease.
Conclusion: Cancer stage, gender, age at diagnosis, and length of time already survived can influence con-
ditional survival for patients with thyroid cancer. Understanding the conditional 5-year disease-specific survival
of well-differentiated thyroid cancer is key to creating treatment plans and tailoring surveillance.
Introduction
In the past 35 years, the incidence rate of thyroid cancerhas risen by nearly 200% (1–6). This increasingly com-
mon cancer has variable prognoses, with most patients hav-
ing an excellent likelihood of long-term survival and others
with an increased risk of death secondary to their cancer (7–
9). Although the 5- and 10-year prognosis at time of diag-
noses is known (3), the likelihood of survival based on how
long a patient has already survived (i.e., conditional survival)
remains understudied.
Understanding conditional survival is important for pa-
tients and providers. It is the key to creating treatment plans,
to determining long-term follow-up/surveillance strategies,
and to giving patients realistic expectations for their future.
For some cancers, patients who survive the first few years
after diagnosis have a much improved life expectancy (10).
For other cancers, likelihood of death persists for many years
(10). In the context of steadily increasing numbers of low-risk
thyroid cancer (3,5), it is important to understand conditional
survival rates based on cancer stage, patient age, and pa-
tient gender. This will allow more tailored treatment and
surveillance.
In this study, we used data from Surveillance, Epide-
miology, and End Results (SEER) registry to determine
conditional 5-year disease-specific survival based on patient
age, gender, and stage. Because patient age has an important
role in determining thyroid cancer outcome (11,12), we hy-
pothesized that age at diagnosis would also be important to
thyroid cancer conditional survival.
Materials and Methods
Data source and study population
Using SEER data we selected patients diagnosed with
well-differentiated thyroid cancer (N = 43,392) between 1998
and 2005. Well-differentiated thyroid cancer included pa-
tients with papillary thyroid cancer, follicular thyroid cancer,
and Hu¨rthle cell cancer. Patients were followed for up to 12
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years with a median follow up of 7.5 years. Tumor stage was
categorized according to SEER summary stage as localized,
regional, or distant. Localized includes single or multifocal
invasive tumor(s) confined to the thyroid or into the capsule
but not beyond. Regional includes direct extension into blood
vessels, cricoid cartilage, esophagus, larynx, nerves, muscles,
and parathyroid. It also includes tumor described as ‘‘fixed
to adjacent tissues’’ and regional lymph node involve-
ment. Distant includes distant lymph nodes, metastasis, and
extension into bone, mediastinal tissues, etc. (3). Age was
categorized by decades, as < 30, 30–39, 40–49, 50–59, 60–
69, 70–79, or ‡ 80 years.
Because this study uses publically available data that
cannot be tracked to human subjects, per the University of
Michigan Institutional Review Board, IRB approval was not
needed.
Statistical analysis
The primary end point was disease-specific survival, de-
fined as the time from diagnosis to death from thyroid cancer,
as determined by SEER. We used Cox proportional hazards
regression to model disease-specific survival as a function of
age and gender.
Given that a patient has survived t years past diagnosis, the
conditional 5-year survival function CS5(t) is the probability
that he or she will survive an additional 5 years. Thus, the
conditional 5-year survival function can formally be defined
as CS5(t)= Pr(T > 5+ tjT > t), where T represents a patient’s
true disease-specific survival (time in years) since diagnosis.
Applying the definition of conditional probability, one can
write CS5(t) = Pr(T > 5 + t)/Pr(T> t) = S(5+ t)/S(t) where S is
the disease-specific survival function. We estimated the
conditional 5-year survival based on estimates of S(5 + t) and
S(t) from the Cox regression model, using the Breslow esti-
mator of the baseline cumulative hazard function.
Results
Table 1 shows the characteristics of the study population.
For thyroid cancer, a large proportion of the patients have
localized disease (62.8%). Only 3.7% of all patients with
thyroid cancer have distant metastases. Thyroid cancer is far
more common in females (76.7%) and among white patients
Table 1. Characteristics of Study Population
Thyroid
Localized Regional Distant Total
Cancer n (%) n (%) n (%) n (%)
Stage 27,267 (62.8) 14,526 (33.5) 1599 (3.7) 43,392 (100.0)
Patient characteristics
Age
< 30 2728 (10.0) 2270 (15.6) 196 (12.3) 5194 (12.0)
30–39 5487 (20.1) 2989 (20.6) 184 (11.5) 8,660 (20.0)
40–49 7049 (25.9) 3407 (23.5) 201 (12.6) 10,657 (24.6)
50–59 5971 (21.9) 2588 (17.8) 272 (17.0) 8831 (20.4)
60–69 3419 (12.5) 1625 (11.2) 277 (17.3) 5321 (12.3)
70–79 2037 (7.5) 1171 (8.1) 298 (18.6) 3506 (8.1)
> 80 576 (2.1) 476 (3.3) 171 (10.7) 1223 (2.8)
Gender
Female 21,796 (79.9) 10,535 (72.5) 930 (58.2) 33,261 (76.7)
Male 5471 (20.1) 3991 (27.5) 669 (41.8) 10,131 (23.3)
Race
White 22,752 (83.4) 12,009 (82.7) 1243 (77.7) 36,004 (83.0)
Black 1899 (7.0) 700 (4.8) 121 (7.6) 2720 (6.3)
Other 2400 (8.8) 1719 (11.8) 225 (14.1) 4344 (10.0)
Unknown 216 (0.8) 98 (0.7) 10 (0.6) 324 (0.7)
Year of diagnosis
1998 1331 (4.9) 869 (6.0) 85 (5.3) 2285 (5.3)
1999 1483 (5.4) 905 (6.2) 105 (6.6) 2493 (5.7)
2000 3,177 (11.7) 1826 (12.6) 211 (13.2) 5214 (12.0)
2001 3524 (12.9) 1930 (13.3) 198 (12.4) 5652 (13.0)
2002 3923 (14.4) 2037 (14.0) 253 (15.8) 6213 (14.3)
2003 4270 (15.7) 2121 (14.6) 234 (14.6) 6625 (15.3)
2004 4606 (16.9) 2363 (16.3) 235 (14.7) 7204 (16.6)
2005 4953 (18.2) 2475 (17.0) 278 (17.4) 7706 (17.8)
Disease-specific survival
Dead 130 (0.5) 525 (3.6) 471 (29.5) 1126 (2.6)
Censored 27,137 (99.5) 14,001 (96.4) 1128 (70.5) 42,266 (97.4)
Overall survival
Dead 2,129 (7.8) 1664 (11.5) 752 (47.0) 4,545 (10.5)
Censored 25,138 (92.2) 12,862 (88.5) 847 (53.0) 38,847 (89.5)
The last date of follow-up was November 2010. Patients who were alive at their last time of follow-up or November 2010 (whichever
came earlier) were considered to be censored at that time point.
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(83%). At the time of last follow-up, only 2.6% of all thyroid
cancer patients died from their cancers.
Prognosis is excellent if the disease is localized. Figure 1
illustrates the conditional 5-year disease-specific survival of
male versus female patients with localized thyroid cancer. A
small age gradient is seen for both genders, demonstrating
better survival for younger patients. For example, for females
with localized disease, the probability of surviving an addi-
tional 5 years, after surviving 2 years past diagnosis [denoted
CS5(2)], is 99.9%, 99.4%, and 96.6% for ages 30–39, 60–69,
and ‡ 80, respectively. For females, the probability of sur-
viving an additional 5 years after surviving 5 years past di-
agnosis [denoted CS5(5)], is 99.9%, 99.3%, and 95.9% for
ages 30–39, 60–69, and ‡ 80, respectively.
Figure 2 shows the conditional 5-year disease-specific
survival of patients with regional thyroid cancer. For thyroid
cancer, the conditional 5-year survival remains relatively
stable over time. For both genders, there is a clear age gra-
dient, with older patients faring worse than younger patients.
For example, for females with regional disease, CS5(2) is
99.9%, 97.0%, and 87.3% for ages 30–39, 60–69, and ‡ 80,
respectively. Five years past diagnosis CS5(5) is 99.9%,
96.3%, and 84.4% for females ages 30–39, 60–69, and ‡ 80,
respectively. However, males generally have a slightly lower
conditional 5-year disease-specific survival.
The conditional 5-year disease-specific survival of patients
with distant metastases from thyroid cancer shows that for
both genders, older patients with thyroid cancer with distant
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FIG. 1. Conditional 5-year
disease-specific survival of
female and male patients
with localized thyroid cancer.
The conditional 5-year dis-
ease-specific survival is near
100% for most patients and is
relatively stable the further
a patient is from time of
diagnosis. Color images
available online at www
.liebertpub.com/thy
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FIG. 2. Conditional 5-year
disease-specific survival of
female and male patients
with regional thyroid cancer.
The conditional 5-year dis-
ease-specific survival differs
by age at diagnosis and is
relatively stable the further
a patient is from time of
diagnosis. Color images
available online at www
.liebertpub.com/thy
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metastases have a worse conditional 5-year survival than
younger patients (Fig. 3). For example, for females with
distant disease, CS5(2) is 97.7%, 71.6%, and 49.2% for ages
30–39, 60–69, and ‡ 80, respectively. Five years past diag-
nosis CS5(5) is 98.1%, 76.4%, and 56.5% for females ages
30–39, 60–69, and ‡ 80, respectively. For both genders, the
conditional 5-year disease-specific survival improves grad-
ually over time.
Table 2 demonstrates disease-specific mortality by age and
gender. For all stages of thyroid cancer, there is a very strong,
linear association between age and disease-specific survival
(for example, age 70–79 versus < 30 years, localized (hazard
ratio [HR] 26.58 [95% confidence interval {CI} 8.08–
163.08)], regional [HR 59.39 (95% CI 30.12–139.87)], and
distant [HR 54.54 (95% CI 20.67–221.42)]. For thyroid
cancer, male gender is associated with a significantly worse
disease-specific survival among patients with regional dis-
ease [HR 1.56 (95% CI 1.31–1.85)] but not among patients
with localized or distant disease.
Discussion
The results of this study provide information to patients
and providers regarding the conditional 5-year disease-
specific survival of patients with thyroid cancer. We found
that age at diagnosis was important for the conditional 5-year
disease-specific survival in all stages of thyroid cancer. We
found that the conditional 5-year disease-specific survival for
localized thyroid cancer was excellent. For patients with re-
gional thyroid cancer the conditional 5-year disease-specific
survival was relatively static over time whereas for distant
thyroid cancer, there was a gradual improvement the longer a
patient lived past time of diagnosis. Male gender was asso-
ciated with significantly worse disease-specific survival for
7
0
20
40
60
80
100
Distant WDTC for Females (N=930)
Co
nd
itio
na
l 5
 Y
ea
r 
D
is
ea
se
−S
pe
cif
ic 
Su
rv
iva
l (%
)
Years Since Diagnosis
Age at 
diagnosis
<30
30−39
40−49
50−59
60−69
70−79
>80_
0 1 2 3 4 5 60 1 2 3 4 5 6 7
0
20
40
60
80
100
Distant WDTC for Males (N=669)
Co
nd
itio
na
l 5
 Y
ea
r 
D
is
ea
se
−S
pe
cif
ic 
Su
rv
iva
l (%
)
Years Since Diagnosis
Age at 
diagnosis
<30
30−39
40−49
50−59
60−69
70−79
>80_
FIG. 3. Conditional 5-year
disease-specific survival of
female and male patients
with distant thyroid cancer.
The conditional 5-year dis-
ease-specific survival differs
by age at diagnosis and im-
proves the further a patient is
from time of diagnosis. Color
images available online at
www.liebertpub.com/thy
Table 2. Disease-Specific Mortality by Age and Gender
Thyroid (N= 43,392)
Localized Regional DistantCancer
Stage HR (95% CI) HR (95% CI) HR (95% CI)
Patient characteristics
Age
< 30 1.00 1.00 1.00
30–39 1.99 (0.50, 13.21) 0.53 (0.16, 1.68) 2.90 (0.84, 13.23)
40–49 1.77 (0.46, 11.62) 2.63 (1.21, 6.54) 9.98 (3.54, 41.77)
50–59 4.03 (1.16, 25.44) 11.69 (5.83, 27.78) 23.81 (8.92, 97.21)
60–69 15.05 (4.58, 92.78) 23.53 (11.81, 55.76) 40.82 (15.42, 165.97)
70–79 26.58 (8.08, 163.90) 59.39 (30.12, 139.87) 54.54 (20.67, 221.42)
> 80 88.67 (26.33, 551.83) 105.20 (52.57, 249.95) 86.80 (32.48, 354.46)
Gender
Female 1.00 1.00 1.00
Male 1.28 (0.86, 1.85) 1.56 (1.31, 1.85) 1.06 (0.89, 1.27)
CI, confidence interval; HR, hazard ratio.
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regional disease (but not for localized or distant disease),
which translates to worse conditional survival for males (an
effect seen primarily in the older age groups).
Although conditional survival has been studied in other
common malignancies, to date, studies have not focused on
the implications of conditional survival on patients with
thyroid cancer with varying age, gender, and stage at time of
diagnosis (10,13–15). Thyroid cancer is the ninth most
common cancer in the United States (16). Despite overall
declines in cancer rates, the incidence of thyroid cancer is
rising (1,2,4). Prognosis for thyroid cancers is generally ex-
cellent, but not all patients have uniformly good long-term
survival. Since incidence is rising and outcome is variable, it
is becoming increasingly important to understand conditional
survival in this cancer.
The importance of age in thyroid cancer outcome has been
studied (17–19). However, this study illustrates the fact that
the importance of age to thyroid cancer outcome is linear and
persists years after diagnosis. Even in patients who are 5
years since the time of diagnosis, age at diagnosis has im-
plications for their conditional 5-year disease-specific sur-
vival, with older patients having worse outcomes than
younger patients.
A possible limitation of this study is that conditional 5-year
disease-specific survival may change over time, especially
with the advent of new therapeutics. However, during the
time span of this study thyroid cancer did not benefit from a
novel therapeutic that would have influenced life expectancy
in a significant and universal manner. Another potential
limitation of this study is the fact that although disease-
specific survival rates are standard outcome measures, they
can underestimate actual cancer-related deaths (20). This
would have the effect of minimizing our findings in the
context of how conditional survival influences long-term
outcomes. Theoretically, reported disease-specific survival
rates may even overestimate cancer-related deaths. However,
disease-specific survival remains the gold standard outcome
measure with large cancer registries.
Despite limitations, this study has relevant findings for
both physicians and patients. Understanding the conditional
5-year disease-specific survival allows physicians to create
management plans. For example, the mortality rate for lo-
calized thyroid cancer is extremely low and the conditional
5-year disease-specific survival excellent. Many of these
patients may be able to be discharged from thyroid cancer
clinics after a few years of surveillance. In contrast, patients
with distant thyroid cancer have a conditional 5-year disease-
specific survival curve that suggests that some patients still
die because of thyroid cancer many years after initial diag-
nosis. These patients likely need long-term surveillance in a
dedicated thyroid cancer clinic. Knowledge of conditional
survival may have implications for changing paradigms in
survivorship care for an increasing number of patients. Un-
derstanding the conditional 5-year disease-specific survival
also allows patients to have a more accurate assessment of
their life expectancy.
The findings from this study are important because the
further a patient is from time of diagnosis, the less relevant
the initial survival estimation and the more pertinent the
conditional survival estimation. The results inform both pa-
tients and their providers and may lead to more tailored
cancer surveillance. Since the number of patients diagnosed
with thyroid cancer continues to increase (4), conditional
survival is becoming increasingly relevant to a greater
number of patients and physicians.
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